mirikizumab
Phase 3- Indications
- Ulcerative colitis
Company intelligence / Profile preview
TLL Pharmaceutical, LLC
Palm Beach Gardens, Florida, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
The company's lead drug Girocitinib (TLL018) is a JAK1/TYK2 inhibitor currently in Phase 3 for Chronic Urticaria. It has shown dose-dependent anti-inflammatory activity and excellent tolerability in preclinical models. A Phase 2 trial for Ulcerative Colitis was withdrawn.
- Therapeutic areas
- GastroenterologyImmunologyDermatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on TLL Pharmaceutical, LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLL Pharmaceutical, LLC.